Curia – CDMO Performance Breakdown & Q1 2023 Business Outlook

  • Private Equity
  • Healthcare
  • North America


Former VP at Albany Molecular Research Inc (AMRI)


  • Significant developments taking place within the CDMO (contract development and manufacturing organisation) sector, focusing on Curia and highlighting outsourcing trends
  • Curia’s biologics service offerings across drug discovery, development and manufacturing capabilities, breaking down strengths and weaknesses
  • Expansion strategy into niche service areas and high-potency compound manufacturing, as well as resulting pricing strategies
  • Curia’s competitive positioning relative to other key players such as Catalent (NYSE: CTLT), Patheon and Lonza (VTX: LONN)
  • 2023 outlook, including potential consolidation activity


Gain access to Premium Content

Submit your details to access up to 5 Forum Transcripts or to request a complimentary one week trial.

    One week, unlimited access to over 40,000 transcripts
The information, material and content contained in this transcript (“Content”) is for information purposes only and does not constitute advice of any type or a trade recommendation and should not form the basis of any investment decision.This transcript has been edited by Third Bridge for ease of reading. Third Bridge Group Limited and its affiliates (together “Third Bridge”) make no representation and accept no liability for the Contentor for any errors, omissions or inaccuracies in respect of it. The views of the specialist expressed in the Content are those of the specialist and they are not endorsed by, nor do they represent the opinion of, Third Bridge. Third Bridge reserves all copyright, intellectual and other property rights in the Content. Any modification, reformatting, copying, displaying, distributing, transmitting, publishing, licensing, creating derivative works from, transferring or selling any Content is strictly prohibited